TabsDetailsBasic DetailsDate: Thursday, March 8, 2018Type: PublicationDescription: The article describes the utilization of drugs with pregnancy exposure registries by trimester during pregnancy, in comparison with matched nonpregnant episodes and a pre-pregnancy period. Among drugs with pregnancy exposure registries, use was less during pregnancy compared with before pregnancy and to the matched nonpregnant episodes. The lower utilization during pregnancy suggests that women may be avoiding these drugs to minimize potentially harmful exposure during pregnancy. This lower utilization may increase the challenges of further studying the safety of these drugs using pregnancy exposure registries. Read More Materials: Pharmacoepidemiol Drug Saf. 2018 Mar 8. doi: 10.1002/pds.4409ContributorsAuthor(s): Onyekachukwu A. Illoh, Sengwee Toh, Susan E. Andrade, Christian Hampp, Leyla Sahin, Kate Gelperin, Lockwood Taylor, Steven T. BirdCorresponding Author: Onyekachukwu A. IllohOffice of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration,10903 New Hampshire Ave, Silver Spring, MD 20993, USA. E-mail address: onyekachukwu.illoh@fda.hhs.gov
